Trial Profile
Phase 2/3, Randomised, Open-Label, Single-Site, Multi-Arm Trial of Ruxolitinib Plus Best Supportive Treatment (BST) versus Fostamatinib Plus BST versus BST for COVID-19 pneumonia
Status:
Recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 04 Jul 2022
Price :
$35
*
At a glance
- Drugs Fostamatinib (Primary) ; Ruxolitinib (Primary)
- Indications COVID-19 pneumonia
- Focus Therapeutic Use
- Acronyms MATIS
- 27 Jun 2022 Planned End Date changed from 1 Dec 2021 to 30 Jun 2022.
- 27 Jun 2022 Planned primary completion date changed from 1 Dec 2021 to 30 Jun 2022.
- 01 Sep 2021 Planned End Date changed from 31 Jul 2021 to 1 Dec 2021.